DO
NBIX icon

denkapparat Operations’s Neurocrine Biosciences NBIX Stock Holding History

denkapparat Operations’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Buy
7,188
+1,374
+24% +$204K 0.4% 72
2026
Q1 		$766K Buy
5,814
+3,240
+126% +$430K 0.32% 116
2025
Q4 		$365K Hold
2,574
– – 0.2% 205
2025
Q3 		$361K Hold
2,574
– – 0.23% 174
2025
Q2 		$324K Hold
2,574
– – 0.26% 162
2025
Q1 		$285K Buy
2,574
+488
+23% +$61.8K 0.3% 141
2024
Q4 		$285K Buy
+2,086
New +$258K 0.42% 99

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

denkapparat Operations's NBIX Position: Q2 2026 in Review

denkapparat Operations increased its Neurocrine Biosciences (NBIX) stake by 24% in Q2 2026, buying an estimated $204K and bringing the position to 7,188 shares worth $1.21M. The position accounts for 0.4% of the portfolio, ranked #72.

denkapparat Operations first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • denkapparat Operations held 7,188 shares of Neurocrine Biosciences worth $1.21M as of Q2 2026.
  • denkapparat Operations bought 1,374 Neurocrine Biosciences shares in Q2 2026, an estimated $204K.
  • Neurocrine Biosciences made up 0.4% of denkapparat Operations's portfolio in Q2 2026, its #72 holding.
  • denkapparat Operations first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on denkapparat Operations's 13F filing for Q2 2026, filed 6 Aug 2026.